Stock KTTA PASITHEA THERAPEUTICS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Pasithea Therapeutics Corp.

Equities

KTTA

US70261F2020

Delayed Nasdaq
Other stock markets
 18:16:04 29/04/2024 BST 		5-day change 1st Jan Change
7.033 USD -2.86% Intraday chart for Pasithea Therapeutics Corp. +2.07% -6.76%
04-24 Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers CI
03-29 Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers
Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004
Top Premarket Decliners
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
Pasithea Therapeutics Shares Rise on FDA Clearance to Evaluate PAS-004 in Advanced Cancer Patients
Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer Patients
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%
Pasithea Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Pasithea Therapeutics Corp. Selects PAS-003 Lead Development Candidate
Pasithea Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Pasithea Therapeutics Corp. announces an Equity Buyback for 5,714,285 shares, for $4 million.
Pasithea Therapeutics Corp. authorizes a Buyback Plan.
Pasithea Therapeutics Corp. Publishes Study in Proceedings of the National Academy of Sciences Related to its PAS-003 Drug Discovery Program
Pasithea Therapeutics' Board Authorizes Share Repurchase Program Through $4 Million Tender Offer; Shares Rise
Pasithea Therapeutics Corp. announces an Equity Buyback for 5,714,285 shares, representing 21.86% for $4 million.
Pasithea Therapeutics Corp. authorizes a Buyback Plan.
Lucy Scientific Discovery Inc. cancelled the acquisition of Pasithea Therapeutics Corp..
Lucy Scientific Discovery Reiterates Proposal to Acquire Pasithea Therapeutics
Pasithea Therapeutics Confirms Unsolicited Takeover Proposal From Lucy Scientific Discovery
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KTTA Stock
  4. News Pasithea Therapeutics Corp.
  5. Other languages